Brazil Pharmaceuticals & Healthcare Market Summary

26 Aug 2010 • by Natalie Aster
Brazil Pharmaceuticals & Healthcare Market Summary
London - According to the research report “Brazil Pharmaceuticals and Healthcare Report Q3 2010” by Business Monitor International Brazil has traditionally been Latin America’s largest pharmaceutical market. The country has lagged behind Mexico since 2001, while both markets saw substantial declines due to regional economic troubles. After rapid growth in the last few years, Brazil’s market has today regained its status as the leading market in the region. Per-capita spending reached just US$91 in 2009, while drug expenditure was equivalent to 1.15% of GDP. Notably, despite strong US dollar growth since 2004, volume sales have been flat or have declined. This is linked both to price rises and the elimination of older, less effective medicines.

Prescription drugs accounted for 75% of the market in 2009. It is noteworthy that Brazilian pharmacies, however, do not always require a prescription to dispense drugs. Therefore the division of sectors is often hard to determine from market statistics. In addition, a significant amount of sales occur through informal outlets, despite repeated attempts to crackdown on this trade. The fastest growing drug sector in Brazil is bioequivalent generics, a trend which shows no signs of abating. While generics represent a large proportion of domestic consumption in volume terms, by value it is less than 20%. The government has toughened GMP requirements for OTC products, a boost for multinational players, and signs of a longer term consolidation in the retail sector should help push less reliable products to the margins.

There are some 550 pharmaceutical firms in Brazil. Leading local producers include Ache/Biosintetica, Medley, Eurofarma, Libbs and EMS-Sigma. Industry investment has recently begun to centre on exports and generics. Of the 2,792 generics registered in Brazil, 89% originate in the country. The presence of 300 imported generic medicines does indicate room for foreign competition, but we note that almost two-thirds of these are of Indian origin.

BMI believes that multinationals looking to enter Brazil will likely remain focused on acquisitions for near-term gain. A host of foreign firms are present in the country, with many stating that investment will continue over the medium term. Indeed, Big Pharma sees Brazil as a strong market in which to increase its emerging market exposure.

More details on the pharmaceuticals & healthcare industries in Brazil can be found from the research study “Brazil Pharmaceuticals and Healthcare Report Q3 2010” published by Business Monitor International.

Title: Brazil Pharmaceuticals and Healthcare Report Q3 2010
July, 2010
Pages: 104
Price: USD 530

To order the report or ask for free sample pages, please contact


MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970